AR077225A1 - Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza - Google Patents

Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza

Info

Publication number
AR077225A1
AR077225A1 ARP100102242A ARP100102242A AR077225A1 AR 077225 A1 AR077225 A1 AR 077225A1 AR P100102242 A ARP100102242 A AR P100102242A AR P100102242 A ARP100102242 A AR P100102242A AR 077225 A1 AR077225 A1 AR 077225A1
Authority
AR
Argentina
Prior art keywords
treatment method
formulations containing
injectable formulations
formulation
containing asenapine
Prior art date
Application number
ARP100102242A
Other languages
English (en)
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of AR077225A1 publication Critical patent/AR077225A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

Formulacion ésta que puede administrarse por medio de un deposito provisto por una inyeccion IM de la formulacion, donde el deposito no presenta una velocidad de liberacion dependiente del tamano de las partículas. Reivindicacion 1: Una formulacion farmacéutica que comprende una suspension acuosa de particulado de la Forma 2 cristalina del hemipamoato de asenapina, en donde el hemipamoato de asenapina está presente en la formulacion en una concentracion que excede por lo menos aproximadamente 10 mg/ml.
ARP100102242A 2009-06-24 2010-06-24 Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza AR077225A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22002709P 2009-06-24 2009-06-24

Publications (1)

Publication Number Publication Date
AR077225A1 true AR077225A1 (es) 2011-08-10

Family

ID=43386952

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102242A AR077225A1 (es) 2009-06-24 2010-06-24 Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza

Country Status (13)

Country Link
US (2) US8658687B2 (es)
EP (1) EP2453870A2 (es)
JP (1) JP5801295B2 (es)
KR (1) KR101435296B1 (es)
CN (1) CN102596172A (es)
AR (1) AR077225A1 (es)
AU (1) AU2010264670A1 (es)
BR (1) BRPI1011453A2 (es)
CA (1) CA2766291C (es)
MX (1) MX2012000061A (es)
RU (1) RU2012102247A (es)
TW (1) TW201113018A (es)
WO (1) WO2010149727A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524920A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Asenapine Hydrochloride Salt Forms
EP2524921A1 (en) * 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Salts of Asenapine
JO3421B1 (ar) * 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
EP2878300B1 (en) * 2012-07-26 2017-05-03 Hisamitsu Pharmaceutical Co., Inc. Patch
CA2890270A1 (en) * 2012-11-01 2014-05-08 Torrent Pharmaceuticals Ltd Pharmaceutical composition of tapentadol for parenteral administration
FR3020810B1 (fr) * 2014-05-06 2016-05-06 Servier Lab Nouveau sel de l'ivabradine et son procede de preparation.
CA2987081C (en) 2015-06-11 2022-08-30 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
BR112019010466A2 (pt) * 2016-12-20 2019-09-10 Lts Lohmann Therapie Systeme Ag sistema terapêutico transdérmico contendo asenapina
KR102614709B1 (ko) 2016-12-20 2023-12-18 에르테에스 로만 테라피-시스테메 아게 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
CA3046128A1 (en) * 2017-01-09 2018-07-12 Asarina Pharma Ab Injectable suspensions
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
AU2018363686B2 (en) * 2017-11-07 2023-11-23 Intervet International B.V. Process for preparing large size isoxazoline particles
BR122023023401A2 (pt) * 2017-11-07 2024-02-20 Intervet International B.V. Composição farmacêutica injetável, usos de um composto isoxazolina e kit compreendendo o referido composto
KR20210022656A (ko) 2018-06-20 2021-03-03 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피 치료 시스템
EP4205745A1 (en) * 2020-08-26 2023-07-05 Shanghai Bocimed Pharmaceutical Co., Ltd. Cariprazine pharmaceutical composition, preparation method and application thereof
WO2023160583A1 (zh) * 2022-02-22 2023-08-31 上海云晟研新生物科技有限公司 卡利拉嗪药用盐及其晶型、药物组合物、制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
ZA933134B (en) * 1992-05-08 1993-11-30 Akzo Nv Depot preparation
EP0569096A1 (en) * 1992-05-08 1993-11-10 Akzo Nobel N.V. Depot preparation
KR100330942B1 (ko) 1994-03-02 2002-11-16 악조 노벨 엔.브이. 설하또는협측투여용약학조성물
EP0984968A1 (en) * 1997-05-26 2000-03-15 Akzo Nobel N.V. Salts of aromatic sulphonic acids
TR200000812T2 (tr) 1997-09-30 2001-07-23 Eli Lilly And Company 2-metil-tieno- benzodiazepin formülasyonu.
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
EP1802301A1 (en) * 2004-10-15 2007-07-04 Pfizer Inc. Treatment of bipolar disorders and associated symptoms
EP1710241B1 (en) * 2005-04-07 2009-11-04 N.V. Organon Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
DOP2006000082A (es) * 2005-04-07 2006-11-30 Organon Ireland Ltd Forma cristalina ortorrómbicadel maleato de asenapina y su uso enel tratamiento de trastornos mentales.
TW200817414A (en) * 2006-07-05 2008-04-16 Organon Nv Process for the preparation of asenapine and intermediate products used in said process
ATE527266T1 (de) 2008-01-04 2011-10-15 Organon Nv Herstellungsverfahren für asenapin und in diesem verfahren verwendete zwischenprodukte

Also Published As

Publication number Publication date
JP2012530759A (ja) 2012-12-06
US20120237561A1 (en) 2012-09-20
RU2012102247A (ru) 2013-07-27
BRPI1011453A2 (pt) 2016-03-15
JP5801295B2 (ja) 2015-10-28
WO2010149727A3 (en) 2011-04-21
US20140154322A1 (en) 2014-06-05
US8658687B2 (en) 2014-02-25
CA2766291C (en) 2016-06-21
AU2010264670A1 (en) 2012-01-19
EP2453870A2 (en) 2012-05-23
KR20120030561A (ko) 2012-03-28
KR101435296B1 (ko) 2014-08-27
MX2012000061A (es) 2012-06-01
CN102596172A (zh) 2012-07-18
TW201113018A (en) 2011-04-16
WO2010149727A2 (en) 2010-12-29
CA2766291A1 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
AR077225A1 (es) Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
CR20120493A (es) Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis
RS52367B (en) GLATIRAMER ACETATE FORMULATION FORMATED VOLUMES AND APPLICATION PROCEDURES
MX2015010083A (es) Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos.
MY188825A (en) High-concentration monoclonal antibody formulations
PE20091184A1 (es) Formas de dosificacion farmaceutica
IN2015KN00005A (es)
AR059097A1 (es) Tratamiento a largo plazo de la infeccion por vih
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
HRP20200704T1 (hr) Vodena formulacija koja sadrži paracetamol i ibuprofen
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
JP2016539921A5 (es)
EA201791138A1 (ru) Фармацевтическая композиция, ее приготовление и применения
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
MX369742B (es) Formulación de liberación modificada.
AR084707A1 (es) Una composicion farmaceutica de combinacion para tratar enfermedades o condiciones asociados al sistema cardiovascular
CL2010000281A1 (es) Formulacion oral en forma de tableta de 9-[(2,2-dimetil-propilamino)-metil]-minociclina; metodo de preparacion; formulacion inyectable del mismo; utiles en el tratamiento de una infeccion.
ECSP11011289A (es) Formulaciones galénicas de compuestos orgánicos
MX2015013155A (es) Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.
PE20130374A1 (es) Composicion farmaceutica que comprende ibuprofeno
RU2007136310A (ru) Способ получения наноразмерной системы доставки лекарственных средств на основе диоксида кремния
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes
WO2015011653A9 (en) pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM
AR079657A1 (es) Formulacion de liberacion sostenida

Legal Events

Date Code Title Description
FA Abandonment or withdrawal